Congratulations to our Digital RESI “Europe” Innovation Challenge Winners!

26 Mar

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN

claireOur 3-day digital RESI “Europe” event came to an end yesterday, and we are very excited to announce the Top 3 Winners of the Innovation Challenge. This was a very special Innovation Challenge for the RESI team as all of the poster presentations were held in digital format, with each finalist company having a dedicated page where you could view their poster, short pitch, and other supplementary materials that the companies made available for viewing.

We will keep our RESI Europe “live agenda” page open to the public for another month, so if you have not had the chance already, please visit Digital RESI Europe Live Agenda to see our virtual exhibit of some amazing technologies across therapeutics, medical devices, diagnostics, and digital health!

We would like to thank every Innovation Challenge company for quickly adapting to our digital transition, and we hope that all companies were able to make the most out of the digitally presented Innovation Challenge.

Congratulations to the Top 3 winners, and thank you all for casting your votes!

First Place: Cerebriu A/S

Click Here to Check Out Cerebriu’s Digital Poster

Cerebriu is dedicated to improving workflow efficiency, quality and patient outcomes in diagnostic imaging.

Our software solution Cerebriu Apollo achieves this by automating image acquisition protocols and triage during MRI brain acquisition providing decision support at key stages of the diagnostic process. We offer workflow efficiency gains that result in improved productivity, better use of resources, and prioritization of the patients who need it most.

Initial focus is brain, namely tumors, haemorrhage and infarcts. Future roadmap expands to additional pathologies, body parts and advanced integration with hospital systems.

Second Place: MOWOOT

Click Here to Check Out MOWOOT’s Digital Poster

MOWOOT is a growth stage medical device company targeting intestinal transit disorders with a purely physical, non-drug, non-invasive solution.

MOWOOT offers a CE certified (Med.Dev. class IIa), IP protected, clinically validated and award-winning technology: the first Intermittent Colonic Exo-peristalsis (ICE) device on the market handling a large unmet need for patients with Neurogenic-Bowel-Disorders (NBD), Idiopathic Chronic Constipation (ICC) and Opioid-Induced-Constipation (OIC).

The Global Market for the indication “chronic constipation” alone has an annual worth of US$ 12.58 bn, with a healthy CAGR of 7.1%, estimated to reach US$ 22,93 bn by 2025.

Third Place: Injeq Oy

Click Here to Check Out Injeq’s Digital Poster

IQ-Needle is a hypodermic needle which can tell where its tip is. This makes demanding blind punctures, such as spinal tap, much easier and safer for the patient. Technology is based on measuring the impedance of the tissue the tip is touching using proprietary stylet design, allowing the needle bosy and styulet to be used as electronic measurement probes. IQ-Needle and Analyzer are in pre-production as we are finalizing clinical trials and starting the CE certification process with TÜV SÜD in Germany.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: